 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Shareholders will begin accepting objections to the merger of Celltrion and Celltrion Healthcare next week.
According to the bio industry on the 20th, Celltrion Group announced its decision to merge the three listed companies on the 17th of last month. Celltrion will merge with Celltrion Healthcare by the end of this year (the first), and integrated Celltrion will merge with Celltrion Pharmaceutical next year (the second). Among them, the date of the first merger is December 28 and the scheduled date of listing of new shares is January 12 next year. 0.4492620 Celltrion common shares per Celltrion Healthcare common share are allocated. In addition, the shareholders' meeting on the approval of the first merger will be held on October 23.
Prior to this, Celltrion and Celltrion Healthcare will receive 'notice of opposition to merger' from shareholders from 25th to October 20th. Shareholders who have expressed their opposition to the merger during the period may exercise their right to purchase stocks from Oct. 23 to Nov. 13. The exercise price of the right to purchase stocks is 158,813 won for Celltrion and 67,251 won for Celltrion Healthcare.
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
